to Indoco Remedies. Piramal Enterprises Limited (‘PEL’, NSE: PEL, BSE: 500302) today announced that it has signed a definitive agreement to sell its clinical research division known as ‘Piramal Clinical Research (PCR)’
via Technology - Latest News http://ift.tt/1KOoQZR
No comments:
Post a Comment